235 related articles for article (PubMed ID: 29174801)
1. Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis.
Lee C; Whang YM; Campbell P; Mulcrone PL; Elefteriou F; Cho SW; Park SI
Cancer Lett; 2018 Feb; 414():205-213. PubMed ID: 29174801
[TBL] [Abstract][Full Text] [Related]
2. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.
Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE
Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062
[TBL] [Abstract][Full Text] [Related]
3. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
Xiang Q; Chen W; Ren M; Wang J; Zhang H; Deng DY; Zhang L; Shang C; Chen Y
Clin Cancer Res; 2014 Jun; 20(11):2959-70. PubMed ID: 24700742
[TBL] [Abstract][Full Text] [Related]
4. Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.
Dai J; Zhang H; Karatsinides A; Keller JM; Kozloff KM; Aftab DT; Schimmoller F; Keller ET
Clin Cancer Res; 2014 Feb; 20(3):617-30. PubMed ID: 24097861
[TBL] [Abstract][Full Text] [Related]
5. The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.
Watanabe K; Hirata M; Tominari T; Matsumoto C; Fujita H; Yonekura K; Murphy G; Nagase H; Miyaura C; Inada M
J Biol Chem; 2016 Sep; 291(40):20891-20899. PubMed ID: 27539855
[TBL] [Abstract][Full Text] [Related]
6. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
Yakes FM; Chen J; Tan J; Yamaguchi K; Shi Y; Yu P; Qian F; Chu F; Bentzien F; Cancilla B; Orf J; You A; Laird AD; Engst S; Lee L; Lesch J; Chou YC; Joly AH
Mol Cancer Ther; 2011 Dec; 10(12):2298-308. PubMed ID: 21926191
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
Mohamedali KA; Li ZG; Starbuck MW; Wan X; Yang J; Kim S; Zhang W; Rosenblum MG; Navone NM
Clin Cancer Res; 2011 Apr; 17(8):2328-38. PubMed ID: 21343372
[TBL] [Abstract][Full Text] [Related]
8. Antitumor agent cabozantinib decreases RANKL expression in osteoblastic cells and inhibits osteoclastogenesis and PTHrP-stimulated bone resorption.
Stern PH; Alvares K
J Cell Biochem; 2014 Nov; 115(11):2033-8. PubMed ID: 25042887
[TBL] [Abstract][Full Text] [Related]
9. Dual blockade of MET and VEGFR2 signaling pathways as a potential therapeutic maneuver for peritoneal carcinomatosis in scirrhous gastric cancer.
Kasai S; Kuwayama N; Motoo Y; Kawashima A; Matsumoto K; Yano S; Matsushima K; Yasumoto K
Biochem Biophys Res Commun; 2022 Apr; 600():80-86. PubMed ID: 35196631
[TBL] [Abstract][Full Text] [Related]
10. Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2.
Navis AC; Bourgonje A; Wesseling P; Wright A; Hendriks W; Verrijp K; van der Laak JA; Heerschap A; Leenders WP
PLoS One; 2013; 8(3):e58262. PubMed ID: 23484006
[TBL] [Abstract][Full Text] [Related]
11. Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling.
Nguyen HM; Ruppender N; Zhang X; Brown LG; Gross TS; Morrissey C; Gulati R; Vessella RL; Schimmoller F; Aftab DT; Corey E
PLoS One; 2013; 8(10):e78881. PubMed ID: 24205338
[TBL] [Abstract][Full Text] [Related]
12. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.
Song EK; Tai WM; Messersmith WA; Bagby S; Purkey A; Quackenbush KS; Pitts TM; Wang G; Blatchford P; Yahn R; Kaplan J; Tan AC; Atreya CE; Eckhardt G; Kelley RK; Venook A; Kwak EL; Ryan D; Arcaroli JJ
Int J Cancer; 2015 Apr; 136(8):1967-75. PubMed ID: 25242168
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.
Kitagawa Y; Dai J; Zhang J; Keller JM; Nor J; Yao Z; Keller ET
Cancer Res; 2005 Dec; 65(23):10921-9. PubMed ID: 16322239
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM
Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946
[TBL] [Abstract][Full Text] [Related]
15. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
[TBL] [Abstract][Full Text] [Related]
16. Cabozantinib and prostate cancer: inhibiting seed and disrupting soil?
Lee RJ; Smith MR
Clin Cancer Res; 2014 Feb; 20(3):525-7. PubMed ID: 24284057
[TBL] [Abstract][Full Text] [Related]
17. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; RĂ©dini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
18. High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells.
Fujita H; Gomori A; Fujioka Y; Kataoka Y; Tanaka K; Hashimoto A; Suzuki T; Ito K; Haruma T; Yamamoto-Yokoi H; Harada N; Sakuragi M; Oda N; Matsuo K; Inada M; Yonekura K
PLoS One; 2016; 11(10):e0164830. PubMed ID: 27736957
[TBL] [Abstract][Full Text] [Related]
19. The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model.
Sampson ER; Martin BA; Morris AE; Xie C; Schwarz EM; O'Keefe RJ; Rosier RN
J Bone Miner Res; 2011 Jun; 26(6):1283-94. PubMed ID: 21308771
[TBL] [Abstract][Full Text] [Related]
20. Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature.
Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Lin DW; Corey E; Nelson PS; Morrissey C
PLoS One; 2021; 16(1):e0245602. PubMed ID: 33471819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]